Education
About Us
Working with TipRanks
Follow Us
Renovorx, Inc. (RNXT)
:RNXT
Top Page
RenovoRx
(NASDAQ:RNXT)
Rating:49Neutral
Price Target:―
Positive Factors
Clinical Trial Progress
RenovoRx is on track to complete enrollment in the 114-patient Phase 3 TIGeR-PaC study, which is crucial for advancing its treatment for pancreatic cancer.
Interim Analysis Results
Positive data from the first interim analysis demonstrated an overall survival of approximately 21.5 months, compared to 15.5 months in the control arm, with a favorable safety profile.
Market Potential
RenovoRx has a significant market potential with its focus on Locally Advanced Pancreatic Cancer, one of the deadliest cancers with very poor prognosis and outcomes.
Negative Factors
Financial Performance
For 1Q25, the company reported $197,000 in revenue and a net loss of $0.08 per diluted share, compared to an estimate of $335,000 and a net loss of $0.07 per diluted share.
Stock Valuation
RenovoRx, with a current valuation, is considered undervalued and could be attractive.
RenovoRx (RNXT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$46.45M
Dividend YieldN/A
Average Volume (3M)188.90K
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue GrowthN/A
EPS Growth61.43%
CountryUS
Employees10
SectorHealthcare
Sector Strength47
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.08
Shares Outstanding36,572,230
10 Day Avg. Volume181,097
30 Day Avg. Volume188,900
Financial Highlights & Ratios
PEG Ratio-0.50
Price to Book (P/B)3.21
Price to Sales (P/S)0.00
P/FCF Ratio-3.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.50Price Target Upside333.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
RenovoRx Business Overview & Revenue Model
Company DescriptionRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
How the Company Makes MoneyRenovoRx generates revenue primarily through the development and commercialization of its RenovoTAMP therapy platform. The company aims to monetize its technology through licensing agreements with pharmaceutical companies and healthcare institutions. Additionally, RenovoRx seeks to establish partnerships and collaborations to further develop its therapeutic applications, which can lead to milestone payments and royalties. The company's financial strategy may also include seeking funding through public and private investments to support ongoing research and development efforts.
RenovoRx Earnings Call Summary
Earnings Call Date:May 15, 2025
(Q1-2025)
| % Change Since: 14.41%|
Next Earnings Date:Aug 13, 2025
Earnings Call Sentiment Positive
The earnings call was predominantly positive, with strong clinical trial results, better-than-expected first-quarter revenue, and robust demand for RenovoCath. However, there were some increases in operating expenses and limited international market presence.Q1-2025 Updates
Positive Updates
Encouraging Clinical Trial Results
The ongoing Phase 3 TIGeR-PaC clinical trial showed that patients experienced median overall survival of 16 months with the targeted approach, compared to 10 months with standard chemotherapy. Additionally, there was a 65% reduction in adverse events such as nausea and fatigue.
First Quarter Revenue Exceeds Expectations
RenovoRx reported approximately $200,000 in revenue from the RenovoCath device, exceeding initial expectations and marking the company's first quarter of commercial sales.
Strong Market Interest and Demand
There is strong organic demand for RenovoCath, with more than 10 new medical institutions initiating purchase orders and repeat orders from initial customers.
New U.S. Patent Issued
RenovoRx announced the issuance of a new U.S. patent for their TAMP therapy platform, further enhancing their intellectual property portfolio.
Financial Stability
The company has $14.6 million in cash, expected to fully fund the RenovoCath scale-up and the Phase 3 TIGeR-PaC clinical trial.
Negative Updates
Increased Operating Expenses
Research and development expenses increased by $0.4 million to $1.7 million, and selling, general, and administrative expenses rose by $0.4 million to $1.6 million, primarily due to increased personnel costs and commercialization efforts.
Limited Current International Market Presence
Currently, there is no CE mark for RenovoCath, and international market expansion is not expected until later in the year or potentially next year.
Company Guidance
During the RenovoRx Q1 2025 financial call, the company highlighted several key metrics and guidance for the future. RenovoRx reported its first revenue of approximately $200,000 from the sale of its FDA-cleared RenovoCath device, surpassing initial expectations. This revenue marks the beginning of commercial sales for the device, which is part of a broader strategy to expand its market presence, targeting a potential U.S. sales opportunity of $400 million annually. The ongoing Phase 3 TIGeR-PaC clinical trial demonstrated promising results, with patients showing a median overall survival of 16 months using the targeted therapy, compared to 10 months with standard chemotherapy, and a significant 65% reduction in adverse events. Research and development expenses increased to $1.7 million from $1.3 million in Q1 2024, driven by enhanced employee compensation and manufacturing costs, while selling, general, and administrative expenses rose to $1.6 million from $1.2 million. The company has $14.6 million in cash, which is expected to fund ongoing clinical trials and commercial scale-up. Looking forward, RenovoRx anticipates continued revenue growth and is exploring strategic partnerships to enhance market penetration.RenovoRx Financial Statement Overview
Summary
RenovoRx faces significant financial challenges with no revenue generation and consistent losses. The balance sheet shows some improvements in equity position, but the company remains highly dependent on external financing, posing risks to its financial stability.Income Statement
RenovoRx has shown consistent negative net income and EBIT over the years, with no revenue generated. The company's lack of revenue growth limits its ability to improve profitability, leading to poor performance in income statement metrics.10
Very Negative
Balance Sheet
The company has managed to reduce its liabilities over the years, resulting in a positive stockholders' equity as of the latest TTM period. However, the absence of revenue and reliance on equity financing pose risks to financial stability.30
Negative
Cash Flow
Operating cash flows remain negative with no free cash flow generation, indicating a heavy reliance on financing activities to sustain operations. While financing cash flow has been positive, it highlights dependence on external funding.20
Very Negative
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -6.00K | -9.00K | 0.00 | 0.00 |
| EBITDA | -6.94M | -11.39M | -9.94M | -5.66M | 0.00 | 0.00 |
| Net Income | -9.16M | -10.23M | -9.77M | -7.10M | -4.38M | -3.78M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.47M | 7.26M | 16.29M | 1.91M | 2.27M |
| Cash, Cash Equivalents and Short-Term Investments | 2.10M | 1.17M | 6.44M | 15.19M | 1.79M | 2.10M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 2.79M | 12.39M |
| Total Liabilities | 0.00 | 4.47M | 1.10M | 938.00K | 16.57M | 13.20M |
| Stockholders Equity | 1.47M | -3.00M | 6.16M | 15.35M | -14.66M | -10.93M |
Cash Flow | ||||||
| Free Cash Flow | -8.75M | -10.26M | -8.81M | -5.93M | -3.53M | -3.35M |
| Operating Cash Flow | -8.75M | -10.26M | -8.81M | -5.92M | -3.53M | -3.35M |
| Investing Cash Flow | 0.00 | 2.03M | -2.03M | -15.00K | 0.00 | -1.00K |
| Financing Cash Flow | 15.09M | 5.01M | 42.00K | 19.33M | 3.20M | 0.00 |
RenovoRx Technical Analysis
Positive
1.27
Price Trends
1.21
Positive
1.10
Positive
1.14
Positive
Market Momentum
0.03
Positive
45.62
Neutral
14.05
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RNXT, the sentiment is Positive. The current price of 1.27 is below the 20-day moving average (MA) of 1.36, above the 50-day MA of 1.21, and above the 200-day MA of 1.14, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 45.62 is Neutral, neither overbought nor oversold. The STOCH value of 14.05 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RNXT.
RenovoRx Risk Analysis
RenovoRx disclosed 67 risk factors in its most recent earnings report. RenovoRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
RenovoRx Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $46.45M | ― | -136.13% | ― | ― | 61.43% | |
49 Neutral | AU$2.48B | 4.33 | -64.25% | 2.85% | 36.51% | 13.14% | |
43 Neutral | $75.44M | ― | -456.32% | ― | ― | 0.13% | |
39 Underperform | $28.20M | ― | -282.07% | ― | ― | -220.54% | |
39 Underperform | $23.16M | ― | -102.99% | ― | ― | 30.37% | |
38 Underperform | $32.12M | ― | -86.78% | ― | ― | -2.37% | |
38 Underperform | $29.25M | ― | 78.50% | ― | ― | 55.52% |
* Healthcare Sector Average
Performance Comparison
RNXT
RenovoRx
1.30
0.16
14.04%
TPST
Tempest Therapeutics
7.13
-19.13
-72.85%
RNTX
Rein Therapeutics
1.54
-1.33
-46.34%
ALXO
ALX Oncology Holdings
0.44
-5.01
-91.93%
SRZN
Surrozen
8.74
-1.11
-11.27%
INKT
MiNK Therapeutics
7.17
-2.03
-22.07%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.